Armata Pharmaceuticals (NYSEAMERICAN:ARMP – Get Free Report) is anticipated to issue its quarterly earnings data before the market opens on Thursday, March 20th. Analysts expect the company to announce earnings of ($0.35) per share and revenue of $1.56 million for the quarter.
Armata Pharmaceuticals Price Performance
ARMP stock opened at $2.05 on Wednesday. Armata Pharmaceuticals has a 52-week low of $1.80 and a 52-week high of $4.25. The stock has a market cap of $74.17 million, a price-to-earnings ratio of -1.25 and a beta of 0.87.
Analyst Ratings Changes
Separately, HC Wainwright reiterated a “buy” rating and issued a $7.00 target price on shares of Armata Pharmaceuticals in a research note on Thursday, December 19th.
About Armata Pharmaceuticals
Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.
See Also
- Five stocks we like better than Armata Pharmaceuticals
- What Are the U.K. Market Holidays? How to Invest and Trade
- Arqit Stock Soars as NVIDIA’s GTC Fuels Quantum Excitement
- 3 Warren Buffett Stocks to Buy Now
- 3 Must-Own Stocks to Build Wealth This Decade
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Advanced Micro Devices Eyes AI Market Growth—Is AMD a Buy?
Receive News & Ratings for Armata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Armata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
